Financial Statements and









(d)



Exhibits.














Exhibit No.







Description





5.1






Opinion of Cooley LLP

.





23.1





Consent of Cooley LLP (included in Exhibit 5.1).








SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.










TRACON Pharmaceuticals, Inc.













Dated: January 13, 2020













By:



/s/ Charles P. Theuer, M.D., Ph.D.













Charles P. Theuer, M.D., Ph.D.











President and Chief Executive Officer











makes a similar move, sign up!

Other recent filings from the company include the following:

Tracon Pharmaceuticals, Inc.'s President and CEO just picked up 5,000 shares - Sept. 25, 2020
Major owner of Tracon Pharmaceuticals, Inc. just picked up 78,734 shares - Sept. 25, 2020
Tracon Pharmaceuticals: Highlights Updated Envafolimab Clinical Results - Sept. 21, 2020
Major owner of Tracon Pharmaceuticals, Inc. just declared owning 1,840,078 shares of Tracon Pharmaceuticals, Inc. - Sept. 17, 2020
Major owner of Tracon Pharmaceuticals, Inc. just picked up 322,471 shares - Sept. 17, 2020

Auto Refresh

Feedback